Genmab: GEN3014's Demise And Implications For The HexaBody Platform
Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Click here to read an ...
William Blair Comments on Genmab A/S FY2029 Earnings
Equities research analysts at William Blair issued their FY2029 earnings per share (EPS) estimates for shares of Genmab A/S ...
Fierce Biotech4d
J&J opts out of licensing Genmab's Darzalex challenger after look at phase 1/2 data
Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter ...
Morgan Stanley Remains a Hold on Genmab (GMAB)
Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Genmab (GMAB – Research Report) today and set a price target of $25.00. The ...
Genmab sinks as J&J opts not to develop Darzalex successor; stock upgraded
Genmab (CSE:GMAB) (NASDAQ:GMAB) announced on Monday, March 10, that Johnson&Johnson (NYSE:JNJ) has chosen not to proceed with the development of GEN3014 (HexaBody-CD38), a next-gen version of their ...
Genmab A/S (NASDAQ:GMAB) Shares Sold by Assetmark Inc.
Assetmark Inc. lowered its position in Genmab A/S (NASDAQ:GMAB – Free Report) by 78.1% during the fourth quarter, Holdings ...
Genmab Stops Blood Cancer Treatment Development After J&J Won't License It
Genmab has stopped clinical development of a blood cancer treatment after Johnson & Johnson decided it won't exercise its option to license it.
Genmab price target lowered to $45 from $50 at Truist
Truist analyst Asthika Goonewardene lowered the firm’s price target on Genmab (GMAB) to $45 from $50 but keeps a Buy rating on the shares.
Genmab Shares Fall After J&J Drops Blood-Cancer Treatment Option
Genmab shares fell on Monday after the company said it would end the development of blood-cancer treatment HexaBody-CD38 because Johnson & Johnson won't exercise its option to license it.
BioPharma Dive2d
A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV
Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is ...
Is Genmab A/S (GMAB) the Best Cash-Rich Undervalued Stock to Invest In?
We recently compiled a list of the 10 Cash-Rich Undervalued Stocks To Invest In. In this article, we are going to take a look ...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in ...